市場調查報告書
商品編碼
843091

出血性疾病的全球市場(各疾病、醫藥品分類、地區):產業展望,綜合分析,未來預測

Bleeding Disorder Treatment Market by Type and by Drug Class : Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018-2025

出版日期: | 出版商: Zion Market Research | 英文 110 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球出血性疾病市場調查,市場及產業概要,各用途、終端用戶、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

第1章 簡介

  • 報告概要與範圍
  • 調查範圍
  • 調查手法

第2章 摘要整理

  • 市場規模的變化與預測(以金額為準)
  • 市場概述

第3章 產業動態

  • 簡介
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 波特的五力分析
  • 市場魅力分析:各市場區隔

第4章 競爭環境

  • 市場佔有率分析
  • 策略趨勢
    • 合併、收購
    • 新材料的登場
    • 協定、夥伴關係、合作、合資企業
    • 研究開發、事業擴大

第5章 出血性疾病的全球市場:各疾病

  • 市場概要
  • A型血友病
  • B型血友病
  • 血友病病(VWD)
  • 其他

第6章 出血性疾病的全球市場:各醫藥品分類

  • 市場概要
  • 血漿來源凝血因子濃縮製劑
  • 重組凝血因子濃縮製劑
  • 去氨加壓素
  • 抗線溶藥
  • 纖維蛋白膠
  • 其他

第7章 出血性疾病的全球市場:各地區

  • 市場概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第8章 企業簡介

  • CSL Behring
  • Bayer AG
  • Novo Nordisk
  • Pfizer Inc.
  • Shire PLC
  • Grifols SA
  • Octapharma
  • Amgen Inc.
  • Cangene Corporation
  • Alnylam Pharmaceuticals
目錄

The report covers a forecast and an analysis of the bleeding disorder treatment market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints of the bleeding disorder treatment market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the bleeding disorder treatment market on a global level.

In order to give the users of this report a comprehensive view of the bleeding disorder treatment market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new product launch, agreements, partnerships, collaborations joint ventures, research development, and regional expansion of major participants involved in the market.

The study provides a decisive view of the bleeding disorder treatment market by segmenting it on the basis of type, drug class, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further division into major countries including the U.S., the UK, Germany, France, China, Japan, India, Brazil, etc.

Some key players of the global bleeding disorder treatment market are Bayer AG, CSL Behring, Novo Nordisk, Pfizer Inc., Shire PLC, Grifols SA, Octapharma, Amgen Inc., Cangene Corporation, and Alnylam Pharmaceuticals.

This report segments the global bleeding disorder treatment market as follows:

Global Bleeding Disorder Treatment Market: Type Analysis

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

Global Bleeding Disorder Treatment Market: Drug Class Analysis

  • Plasma-Derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytic
  • Fibrin Sealants
  • Others

Global Bleeding Disorder Treatment Market: Regional Analysis

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa

Table Of Contents

Chapter 1. Introduction

  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology

Chapter 2. Executive Summary

  • 2.1. Global bleeding disorder treatment market, 2016-2025 (USD Billion)
  • 2.2. Global bleeding disorder treatment market: Snapshot

Chapter 3. Bleeding Disorder Treatment Market - Market Dynamics

  • 3.1. Introduction
  • 3.2. Market drivers
    • 3.2.1. Global bleeding disorder treatment market drivers: Impact analysis
    • 3.2.2. The increasing prevalence of bleeding disorders
    • 3.2.3. Government initiatives
    • 3.2.4. Technological advancements
  • 3.3. Market Restraints
    • 3.3.1. Global bleeding disorder treatment market restraints: Impact analysis
    • 3.3.2. Counterfeit treatments
    • 3.3.3. Reimbursement policies
    • 3.3.4. High treatment cost
  • 3.4. Opportunities
    • 3.4.1. R&D activities for the development of recombinant products
  • 3.5. Porter's Five Forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. The threat from new entrants
    • 3.5.4. The threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by type
    • 3.6.2. Market attractiveness analysis, by drug class
    • 3.6.3. Market attractiveness analysis, by region

Chapter 4. Global Bleeding Disorder Treatment Market - Competitive Landscape

  • 4.1. Company market share analysis
    • 4.1.1. Global bleeding disorder treatment market: company market share, 2018
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New material launch
    • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
    • 4.2.4. Research and development and regional expansion

Chapter 5. Global Bleeding Disorder Treatment Market - Type Analysis

  • 5.1. Global bleeding disorder treatment market: Type overview
    • 5.1.1. Global bleeding disorder treatment market revenue share, by type, 2018 and 2025
  • 5.2. Hemophilia A
    • 5.2.1. Global bleeding disorder treatment market for hemophilia A, 2016-2025 (USD Billion)
  • 5.3. Hemophilia B
    • 5.3.1. Global bleeding disorder treatment market for hemophilia B, 2016-2025 (USD Billion)
  • 5.4. Von Willebrand disease
    • 5.4.1. Global bleeding disorder treatment market for Von Willebrand disease, 2016-2025 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global bleeding disorder treatment market for others, 2016-2025 (USD Billion)

Chapter 6. Global Bleeding Disorder Treatment Market - Drug Class Analysis

  • 6.1. Global bleeding disorder treatment market: Drug Class overview
    • 6.1.1. Global bleeding disorder treatment market revenue share, by drug class, 2018 and 2025
  • 6.2. Plasma-derived Coagulation Factor Concentrates
    • 6.2.1. Global bleeding disorder treatment market for plasma-derived coagulation factor concentrates pharmacies, 2016-2025 (USD Billion)
  • 6.3. Recombinant Coagulation Factor Concentrates
    • 6.3.1. Global bleeding disorder treatment market for recombinant coagulation factor concentrates, 2016-2025 (USD Billion)
  • 6.4. Desmopressin
    • 6.4.1. Global bleeding disorder treatment market for desmopressin, 2016-2025 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global bleeding disorder treatment market for others, 2016-2025 (USD Billion)

Chapter 7. Global Bleeding Disorder Treatment Market - Regional Analysis

  • 7.1. Global bleeding disorder treatment market: Regional overview
    • 7.1.1. Global bleeding disorder treatment market revenue share, by region, 2018 and 2025
  • 7.2. North America
    • 7.2.1. North America bleeding disorder treatment market, 2016-2025 (USD Billion)
    • 7.2.2. North America bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
    • 7.2.3. North America bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.2.4. The U.S.
      • 7.2.4.1. The U.S. bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.2.4.2. The U.S. bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.2.5. Canada
      • 7.2.5.1. Canada bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.2.5.2. Canada bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe bleeding disorder treatment market, 2016-2025 (USD Billion)
    • 7.3.2. Europe bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
    • 7.3.3. Europe bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.3.4. UK
      • 7.3.4.1. UK bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.3.4.2. UK bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.3.5. Germany
      • 7.3.5.1. Germany bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.3.5.2. Germany bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.3.6. France
      • 7.3.6.1. France bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.3.6.2. France bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.3.7. Rest of Europe
      • 7.3.7.1. Rest of Europe bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.3.7.2. Rest of Europe bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific bleeding disorder treatment market, 2016-2025 (USD Billion)
    • 7.4.2. Asia Pacific bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
    • 7.4.3. Asia Pacific bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.4.4. China
      • 7.4.4.1. China bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.4.4.2. China bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.4.5. Japan
      • 7.4.5.1. Japan bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.4.5.2. Japan bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.4.6. India
      • 7.4.6.1. India bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.4.6.2. India bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.4.7. Rest of Asia Pacific
      • 7.4.7.1. Rest of Asia Pacific bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.4.7.2. Rest of Asia Pacific bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America bleeding disorder treatment market, 2016-2025 (USD Billion)
    • 7.5.2. Latin America bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
    • 7.5.3. Latin America bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.5.4. Brazil
      • 7.5.4.1. Brazil bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.5.4.2. Brazil bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.5.5. Rest of Latin America
      • 7.5.5.1. Rest of Latin America bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.5.5.2. Rest of Latin America bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
  • 7.6. The Middle East and Africa
    • 7.6.1. The Middle East and Africa bleeding disorder treatment market, 2016-2025 (USD Billion)
    • 7.6.2. The Middle East and Africa bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
    • 7.6.3. The Middle East and Africa bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)

Chapter 8. Company Profile

  • 8.1. CSL Behring
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Product Portfolio
    • 8.1.4. Business Strategy
    • 8.1.5. Recent Developments
  • 8.2. Bayer AG
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Product Portfolio
    • 8.2.4. Business Strategy
    • 8.2.5. Recent Developments
  • 8.3. Novo Nordisk
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Product Portfolio
    • 8.3.4. Business Strategy
    • 8.3.5. Recent Developments
  • 8.4. Pfizer Inc.
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Product Portfolio
    • 8.4.4. Business Strategy
    • 8.4.5. Recent Developments
  • 8.5. Shire PLC
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Product Portfolio
    • 8.5.4. Business Strategy
    • 8.5.5. Recent Developments
  • 8.6. Grifols SA
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Product Portfolio
    • 8.6.4. Business Strategy
    • 8.6.5. Recent Developments
  • 8.7. Octapharma
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Product Portfolio
    • 8.7.4. Business Strategy
    • 8.7.5. Recent Developments
  • 8.8. Amgen Inc.
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Product Portfolio
    • 8.8.4. Business Strategy
    • 8.8.5. Recent Developments
  • 8.9. Cangene Corporation
    • 8.9.1. Overview
    • 8.9.2. Financials
    • 8.9.3. Product Portfolio
    • 8.9.4. Business Strategy
    • 8.9.5. Recent Developments
  • 8.10. Alnylam Pharmaceuticals
    • 8.10.1. Overview
    • 8.10.2. Financials
    • 8.10.3. Product Portfolio
    • 8.10.4. Business Strategy
    • 8.10.5. Recent Developments